Loading
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Regular session
$153.62
−$2.46 · -1.58%
Regular session · ET · Market data may be delayed.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Day range
Current $153.62
52-week range
Current $153.62
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
57
Mixed
Risk
47
Elevated Risk
Momentum
49
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Day range
Current $153.62
52-week range
Current $153.62
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 45.38M USD | 29.94M USD | 24.84M USD | 8.87M USD | 7.42M USD |
| Selling, general, and administrative | 38.83M USD | 10.06M USD | 6.82M USD | 3.95M USD | 2.38M USD |
| Operating expenses | 84.21M USD | 40M USD | 31.67M USD | 12.82M USD | 9.8M USD |
| Interest income | — | 3.74M USD | 74K USD | 23K USD | 5K USD |
| Interest expense | — | 20K USD | 25K USD | 16K USD | — |
| Depreciation and amortization | 464K USD | 449K USD | 399K USD | 198K USD | 30K USD |
| Operating income | −84.21M USD | −40M USD | −31.67M USD | −12.82M USD | −9.8M USD |
| Net income | −77.61M USD | −36.14M USD | −31.63M USD | −12.65M USD | −9.67M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$245.83
60.02% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR Portfolio Emerging Markets ETFSPEM4.72M0.03%17.88B USD0.07%$51.50-1.34%
ICBC CSOP S&P New China Sectors ETF3167.HK860.74K0.23%368.6M HKD1.13%HK$55.16-1.18%
ActivePassive International Equity ETFAPIE656.47K0.06%1.17B USD0.45%$38.35-0.60%
Fidelity Nasdaq Composite Index ETFONEQ584.52K0.01%10.94B USD0.21%$107.08-1.27%
State Street SPDR S&P China ETFGXC501.07K0.11%455.03M USD0.59%$84.59-0.90%
Virtus Biotech Clinical Trials ETFBBC358.52K0.87%41.11M USD0.65%$42.07-2.81%
Even Herd Long Short ETFEHLS201.83K0.34%58.83M USD2.62%$25.44-0.25%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM66.45K0.01%688.21M USD0.89%$57.0881-0.07%State Street SPDR Portfolio Emerging Markets ETFSPEMICBC CSOP S&P New China Sectors ETF3167.HKActivePassive International Equity ETFAPIEFidelity Nasdaq Composite Index ETFONEQState Street SPDR S&P China ETFGXCVirtus Biotech Clinical Trials ETFBBCEven Herd Long Short ETFEHLSMorgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
